Last deal

$135M

Amount

Series B

Stage

01.03.2023

Date

3

all rounds

$260M

Total amount

General

About Company
Chroma Medicine revolutionizes treatment of genetic diseases with single-dose epigenetic medicines.

Industry

Sector :

Subsector :

Keywords :

founded date

01.01.2021

Number of employees

Company Type

For Profit

Last funding type

Series B

IPO status

Private

Description

By harnessing epigenetics, Chroma Medicine is developing a cutting-edge approach to gene regulation that allows for precise control of gene activity without altering the DNA sequence. Their groundbreaking research in precision genomics is leading to the creation of a new class of therapeutics, providing unparalleled control of gene expression and offering innovative treatment options for genetically driven diseases.
Contacts

Phone number

Social url